Fig. 2: Poor clinical uptake of NTRK-targeted therapy.
From: Real-world evidence provides clinical insights into tissue-agnostic therapeutic approvals
A Clinical uptake of NTRK-targeted therapies (larotrectinib or entrectinib) from 2019 to 2022. A total of 81 patients were treated with NTRK inhibitors out of 216 patients with tumors positive for NTRK fusions (37.5%). Percentages may add up to greater than 100% due to rounding. B Immune-oncology (IO) biomarker prevalence in patients treated (n = 81) or not treated (n = 135) with NTRK-targeting drugs. Statistical significance was calculated using Fisher’s exact test.
